Metagenomi Therapeutics, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies. The company uses a proprietary metagenomics-derived toolbox to discover and engineer genome-editing systems, including nucleases, base editors, and gene-integration technologies. Its platform is designed to support precise DNA changes across a wide range of genetic targets, with current work centered on therapeutic programs for serious inherited conditions such as hemophilia and other genetic diseases. Metagenomi Therapeutics also collaborates with partners in biotechnology and pharmaceutical research to expand the potential uses of its editing technologies. Headquartered in Emeryville, California, Metagenomi Therapeutics, Inc. plays a role in the growing field of next-generation genetic medicine, where genome editing is being developed as a foundational approach to treating disease at its source.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jian Irish M.B.A., Ph.D.
- Employees
- 113
- Headquarters
- EmeryVille, CA, United States
- Website
- metagenomi.co